Sarepta’s revenues fell as Michael Severino took the CEO role; Arcturus took back rights to its mRNA COVID-19 vaccine; Iovance and Viridian saw encouraging signs for their approved products; and Roivant is getting ready to launch brepocitinib.
Sarepta’s revenues fell as Michael Severino took the CEO role; Arcturus took back rights to its mRNA COVID-19 vaccine; Iovance and Viridian saw encouraging signs for their approved products; and Roivant is getting ready to launch brepocitinib.